iRadimed appoints Hilda Scharen-Guivel to Board of Directors, effective Oct 4, 2022

IRADIMED CORP

Board expanded to five directors; three are independent, including Scharen-Guivel.
Scharen-Guivel recently retired from FDA as Program Director of CDRH; 25+ years in federal agencies.
She will receive standard non-employee director compensation per 2022 proxy statement.
Scharen-Guivel has no material relationship with iRadimed; no transactions under Item 404(a).

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Hilda Scharen-Guivel

Director

IRMD · IRADIMED CORP

Effective: 2022-10-04
Filed: October 6, 2022, 7:59 PM ET

elected Ms. Hilda Scharen-Guivel as a Director, both effective October 4, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Hilda Scharen-Guivel was elected as Director at IRADIMED CORP.

Action: elected
Role: Director

Exact text from the filing

elected Ms. Hilda Scharen-Guivel as a Director, both effective October 4, 2022.

View on SEC.gov

IRADIMED CORP filing history →

Source: SEC EDGAR

accession 0000898432-22-000615

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.